常规延迟骨盆显像在生化复发前列腺癌68Ga-PSMA PET/CT中的诊断价值
该研究回顾性分析201例因生化复发(BCR)接受双时相68Ga-PSMA PET/CT的前列腺癌患者(中位PSA 0.52 ng/mL),评估注射后约90分钟延迟骨盆显像是否改善复发灶诊断。结果显示延迟显像提高了68例(34%)的诊断确定性,为23例(11%)发现额外病灶,约三分之一额外病灶患者(占总队列3%)据此在治疗计划中接受了局部放疗剂量提升。
要点
- 延迟骨盆显像提高34%患者的诊断确定性,11%患者发现额外病灶。
- 额外病灶患者中约三分之一(总队列3%)据此调整治疗计划接受局部放疗剂量提升。
- 恶性病灶中位SUVmax由4.3升至5.0,良性病灶保持稳定(2.7 vs 2.6)。
核心结论
- 注射后90分钟常规延迟骨盆显像可提高前列腺癌生化复发患者的病灶检出率和诊断信心,尤其在PSA低于1 ng/mL时。
研究设计与样本
- 回顾性分析201例因前列腺癌生化复发接受双时相68Ga-PSMA PET/CT的患者,中位PSA为0.52 ng/mL。
- 约60分钟采集头顶至大腿中段图像,约90分钟采集延迟骨盆图像,由两名核医学医师独立评估延迟显像是否提高诊断确定性或揭示额外68Ga-PSMA亲和病灶。
主要发现
- 延迟骨盆显像提高68例(34%)患者的诊断确定性,并为23例(11%)患者揭示额外68Ga-PSMA亲和病灶。
- 延迟显像检出额外病灶的患者中约三分之一(占总队列3%)随后在治疗计划中接受局部放疗剂量提升。
- 改善主要源于示踪剂摄取增加确认细微病灶、减少膀胱或输尿管干扰以及区分生理性与病理性摄取。
- 恶性病灶中位SUVmax从4.3升至5.0,良性病灶保持稳定(常规显像中位SUVmax 2.7,延迟显像2.6)。
临床怎么用
- 在标准PSMA PET/CT协议中加入注射后90分钟延迟骨盆采集,可改善分期准确性与临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The detection of biochemical recurrence (BCR) of prostate cancer remains challenging, as small-volume disease may fall below the sensitivity of standard imaging. Prostate-specific membrane antigen (PSMA) PET/CT is currently the most sensitive imaging modality for tumor detection at low prostate-specific antigen (PSA) levels, but recurrence continues to be difficult to detect. We evaluated whether routine delayed pelvic imaging at 90 min postinjection improves diagnosis of sites of recurrence in patients referred for BCR. Methods: We retrospectively analyzed 201 patients with prostate cancer undergoing dual-phase 68Ga-PSMA PET/CT for BCR of prostate cancer (median PSA, 0.52 ng/mL). Imaging of vertex to midthighs was acquired at approximately 60 min and delayed pelvic imaging at approximately 90 min postinjection. Two nuclear medicine physicians independently assessed whether delayed imaging improved diagnostic certainty or revealed additional 68Ga-PSMA-avid lesions. Results: Delayed pelvic imaging improved diagnostic certainty for 68 patients (34%) and revealed additional 68Ga-PSMA-avid lesions for 23 patients (11%). Of patients with additional lesions detected on delayed imaging, roughly one third-representing 3% of the total cohort-subsequently received focal radiation dose escalation during treatment planning. Improvements were primarily influenced by increased tracer uptake confirming subtle lesions, reduced bladder or ureteral interference, and differentiation of physiologic from pathologic uptake. All measurable lesions within the field of view of the delayed pelvic image were quantified. The median SUVmax for malignant lesions increased from 4.3 to 5.0, whereas benign lesions remained stable (median SUVmax of 2.7 on normal imaging and 2.6 on delayed imaging). Conclusion: Routine delayed pelvic imaging at 90 min postinjection enhanced lesion detection and diagnostic confidence in BCR of prostate cancer, particularly at low (<1 ng/mL) PSA levels. The addition of this additional acquisition into standard PSMA PET/CT protocols can improve staging accuracy and clinical decision-making.
引用
- Jia KY, Kuten J, Jia HY, et al. Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing 68Ga-PSMA PET/CT. J Nucl Med. 2026. PMID: 42242869. doi:10.2967/jnumed.126.272009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。